Pharmaceutical composition of hydrochlorothiazide:β-cyclodextrin: Preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation

Molecules

Volumn 16, Issue 6, 2011, Pages 4482-4499

  Pires, Maria Arlete Silva ^a   Dos Santos, Robson Augusto Souza ^a   Sinisterra, Rubén Dario ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

cyclodextrin; Diuretic; Hydrochlorothiazide; Intrinsic dissolution

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; INFRARED SPECTROSCOPY; KIDNEY CONCENTRATING CAPACITY; MALE; NUCLEAR MAGNETIC RESONANCE; POWDER; RAT; SOLUBILITY; WISTAR RAT; X RAY DIFFRACTION;

ANIMALS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; DIURETICS; HYDROCHLOROTHIAZIDE; KIDNEY CONCENTRATING ABILITY; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; POWDERS; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 79959584971     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16064482     Document Type: Article

References (33)

1. Zappe, D.; Papst, C.C.; Ferbe, P. Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control. Vas. Health Risk Manag. 2009, 5, 883-892.
2. Ladak, N.; Thompson, J. Drugs acting on the heart: Antihypertensive drugs. Anaesth. Intensive Care Med. 2009, 10, 392-395.
3. Jensen, C.E.; Santos, R.A.S.; Denadai, A.M.L.; Santos, C.F.F.; Braga, A.N.G.; Sinisterra, D.S. Pharmaceutical composition of valsartan:β- cyclodextrin: Physico-chemical characterization and anti-hypertensive evaluation. Molecules 2010, 15, 4067-4084.
4. Mahmud, A.; Feely, J. Low-dose quadruple antihypertensive combination more efficacious than individual agents - a preliminary report. Hypertension 2007, 49, 272-275. (Pubitemid 46143001)
5. Hoes, A.W.; Grobbee, D.E.; Peet, T.M.; Lubsen, J. Do non-potassium- sparing diuretics increase the risk of sudden cardiac death in hypertensive patients? Recent evidence. Drugs 1994, 47, 711-733. (Pubitemid 24151093)
6. Opie, L.H.; Kaplan, N.M. Diuretics. In Drugs for the Heart, 3rd ed.; Opie, L.H., Ed.; W.B. Saunders Co.: Philadelphia, PA, USA, 1991; pp. 74-99.
7. Field, M.J.; Stanton, B.A.; Giebisch, G.H. Differential acute effects of aldosterone, dexamethasone and hyperkalemia on distal tubular potassium secretion in the rat kidney. J. Clin. Invest. 1984, 74, 1792-1802. (Pubitemid 15214093)
8. Loftsson, T. Cyclodextrins and the biopharmaceutics classification system of Drugs. J. Incl. Phenom. Macro. Chem. 2002, 44, 63-67. (Pubitemid 38075665)
9. Loftsson, T.; Duchêne, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007, 329, 1-11. (Pubitemid 44937538)
10. Brewster, M.E.; Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Deliver. Rev. 2007, 59, 645-666. (Pubitemid 47299263)
11. Szejtli, J. Introduction and general overview of cyclodextrin chemistry. Chem. Rev. 1998, 98, 1743-1753. (Pubitemid 128633435)
12. Challa, R.; Ahuja, A.; Ali, J.; Khar, R.K. Cyclodextrins in drug delivery: An updated review. AAPS Pharm. Sci. Tech. 2005, 6, E329-E357.
13. Martin Del Valle, E.M. Cyclodextrins and their uses: A review. Process Biochem. 2004, 39, 1033-1046.
14. Nalluri, B.N.; Chowdary, K.P.R.; Murthy, K.V.R.; Becket, G.; Crooks, P.A. Tablet formulation studies on nimesulide and meloxicam-cyclodextrin binary systems. AAPS Pharm. Sci. Tech. 2007, 8, E1-E7.
15. Denadai, A.M.L.; Santoro, M.M.; Silva, L.H.; Viana, A.T.; Santos, R.A.S.; Sinisterra, R.D. Sel-assembly characterization of the β-cyclodextrin and hydrochlorothiazide system: NMR, phase solubility, ITC and QELS. J. Incl. Phenom. Macrocycl. Chem. 2006, 55, 41-49. (Pubitemid 43873483)
16. Davis, M.E.; Brewster, M.E. Cyclodextrin-based pharmaceutics: Past, presentand future. Nat. Rev. Drug Discov. 2004, 3, 1023-1035. (Pubitemid 39642365)
17. Acecves-Hermandez, J.M.; Agacino-Valdés, E.; Paz, M.; Hinojosa-Torres, J. Experimental and theoretical study of the conformational analysis of hydrochlorothiazide. J. Mol. Struct. 2006, 786, 1-8.
18. Sousa, F.B.; Denadai, A.M.L.; Lula, I.S.; Nascimento, C.S.; Fernandes, G.S.N.; Lima, A.C.; Ameida, W.B.; Sinisterra, R.D. Supramolecular self-assembly of cyclodextrin and higher water soluble guest: Thermodynamics and topological studies. J. Am. Chem. Soc. 2008, 130, 8426-8436. (Pubitemid 351898563)
19. Russell, N.R.; McNamara, M. FT-IR and Raman spectral evidence for metal complex formation with β-ciclodextrin as a first sphere ligand. J. Incl. Phen. Macr.Chem. 1989, 7, 455-640.
20. Zhanga, G.G.Z.; Lawa, D.; Schmittb, E.A.; Qiub, Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv. Drug Deliv. Rev. 2004, 56, 371-390.
21. Zang, X.; Wu, D.; Lai, J.; Lu, Y.; Yin, Z.; Wu, W. Piroxican/2- hydroxypropyl-β-cyclodextrin inclusion complex prepared by a new fluid-bed coating techning. J. Pharm. Sci. 2009, 98, 665-675.
22. Kohata, S.; Kouki, J.; Akirsa, O. Thermal decomposition of cyclodextrins (α-, β-, γ- and modified β-CyD) and of metal-(β-CyD) complexes in the solid phase. Termochim. Acta. 1993, 217, 187-198.
23. Menon, D.; El-Ries, M.; Alexander, K.S.; Riga, A.; Dollimore, D. A thermal analysis study of the decomposition of hydrochlorothiazide. Instrum. Sci. Technol. 2002, 30, 329-340.
24. Blagden, N.; de Matas, M.; Gavan, P.T.; York, P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Delivery Rev. 2007, 59, 617-630. (Pubitemid 47285407)
25. The United States pharmacopeia, 31st ed.; The United States Pharmacopeial Convention: Rockville, MD, USA, 2007; p. 1087.
26. Kaukonem, A.M.; Lennernas, H.; Mannerman, J.P. Water-soluble β-cyclodextrins in paediatric oral solutions of spironolactone: Preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats. J. Pharm. Pharmacol. 1998, 50, 611-619. (Pubitemid 28297224)
27. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A Theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution an in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
28. Lu, Y.; Zang, X.; Lai, J.; Yin, Z.; Wu, W. Physical characterization of meloxican-β-cyclodextrin inclusion complex prepared by a fluid-bed method. Particuology 2009, 7, 1-8.
29. Schneider, H.J.; Hacket, F.; Rüdiger, V.; Ikeda, H. NMR studies of cyclodextrins and cyclodextrin complexes. Chem. Rev. 1998, 98, 1755-1785. (Pubitemid 128633436)
30. Werner, M.H. Advanced User's Guide, Brucker. <940712>; Spectrospin A.G.: Fallanden, Switzerland, 1994.
31. Rahman, A. One and Two Dimensional NMR Spectroscopy, 1st ed.; Elsevier: New York, NY, USA, 1989.
32. Mougenot, N.; Médiani, O.; Lechat, P. Bisoprolol and hydroclorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats. Pharmacol. Res. 2005, 51, 359-365. (Pubitemid 40430810)
33. Materson, B. Historical perpesctive of low- vs. high-dose diuretics. J. Am. Soc. Hypertens. 2007, 373-380. (Pubitemid 350182997)